AGL

Glycogen debranching enzyme · P35573 · AGL on Sugi Atlas →

2,430 patent compounds predicted against AGL, 1,386 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Duvoglustat (SCHEMBL2969)	1.00	3/20
Duvoglustat (SCHEMBL142573)	1.00	3/20
Deoxymannojirimycin (SCHEMBL329674)	1.00	3/20
SCHEMBL466573	1.00	3/20
SCHEMBL466574	1.00	3/20
Duvoglustat (SCHEMBL1479364)	1.00	3/20
Duvoglustat (SCHEMBL1527007)	1.00	3/20
Duvoglustat (SCHEMBL1527009)	1.00	3/20
Duvoglustat (SCHEMBL2163281)	1.00	3/20
Duvoglustat (SCHEMBL2434068)	1.00	3/20
SCHEMBL2434435	1.00	3/20
SCHEMBL2435218	1.00	3/20
SCHEMBL2435520	1.00	3/20
SCHEMBL2437378	1.00	3/20
Deoxymannojirimycin (SCHEMBL3367857)	1.00	3/20
SCHEMBL4319863	1.00	3/20
Deoxymannojirimycin (SCHEMBL4323978)	1.00	3/20
Duvoglustat (SCHEMBL4330678)	1.00	3/20
Duvoglustat (SCHEMBL4619759)	1.00	3/20
SCHEMBL6135379	1.00	3/20

Clinical trials — most relevant to AGL by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Growth and Development Study of Alglucosidase Alfa	PHASE4	COMPLETED
Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity	PHASE4	COMPLETED
Late-Onset Treatment Study Extension Protocol	PHASE4	COMPLETED
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses	PHASE2	COMPLETED
Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body Disease	PHASE2	COMPLETED
A Double-Blind, Placebo-Controlled Study of Fermented Deglycyrrhizinated Licorice Extract	PHASE2	COMPLETED
Study of ORL-1G (D-galactose) in Patients With Glycogen Storage Disease Type 14	PHASE1/PHASE2	UNKNOWN
French Observatory for Patients with Type 3 Glycogenosis	nan	RECRUITING
Effect of an Polyphenolic Beverage in Healthy Volunteers	nan	ACTIVE_NOT_RECRUITING
Acute Nutritional Ketosis in GSD IIIa	nan	COMPLETED
Biomarker for Glycogen Storage Diseases (BioGlycogen)	nan	WITHDRAWN
Diet and Exercise in Pompe Disease	nan	COMPLETED
Hepatic Glycogen and Fat Oxidation	nan	COMPLETED
McArdle Disease Treatment by Ketogenic Diet	nan	COMPLETED
The Role of Sugars in Fat Accumulation in the Liver	nan	RECRUITING
Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia	nan	UNKNOWN
Biomarker for Pompe Disease (BioPompe)	nan	WITHDRAWN
Galactose Mediated Glycogen Resynthesis	nan	COMPLETED
Non Invasive Assessment of Liver Glycogen Kinetics and ATP Synthesis in Type1 Diabetics	nan	COMPLETED
Growth Hormone Use in Adolescents and Adults With Cystic Fibrosis	nan	WITHDRAWN
Effect of Glycogen Replenishment on Time Trial Performance Following a Glycogen Lowering Exercise	nan	UNKNOWN
Effect of Meal Timing in T2D on Hepatocytes SRIT1 and Clock Genes	nan	UNKNOWN
GBE Deficiency (GSD IV and APBD) Natural History Study	nan	RECRUITING
Role of the Liver in Glucose Homeostasis Using Metabolic Imaging	nan	COMPLETED
An MRI Study on Muscular Diseases -Pompe Disease and Dystrophia Myotonica-	nan	UNKNOWN
Effects of Polyphenols Found in Pomegranate and Olives Food Supplements on Postprandial Blood Glucose in Vivo.	nan	COMPLETED
Cardiopulmonary Exercise Test to Quantify Enzyme Replacement Response in Pediatric Pompe Disease	nan	COMPLETED
Effects of Dual-Source Carbohydrate Intake and Liver Glycogen Repletion After Overnight Fasting.	nan	NOT_YET_RECRUITING
Does Insulin Requirement Post Cardiac Surgery Predicts The Risk Of Developing Diabetes	nan	UNKNOWN
Study of Glycogen Storage Disease and Associated Disorders	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a AGL binder may also engage these)

Protein	Name	Similarity
A8BQB4	—	1.000	A8BQB4 →
Q2PQH8	—	1.000	Q2PQH8 →
P35574	—	1.000	P35574 →
Q8N1G2	—	0.983	Q8N1G2 →
Q60HE5	—	0.981	Q60HE5 →
Q803R5	—	0.981	Q803R5 →
Q94A08	—	0.981	Q94A08 →
NAT10	RNA cytidine acetyltransferase	0.981	landscape →
Q9DBC3	—	0.980	Q9DBC3 →
Q69Q02	—	0.980	Q69Q02 →
Q5U2Z5	—	0.979	Q5U2Z5 →
P42898	—	0.979	P42898 →
Q9WU20	—	0.978	Q9WU20 →
Q9SE94	—	0.978	Q9SE94 →
Q04499	—	0.978	Q04499 →
Q8CIG8	—	0.978	Q8CIG8 →
Q5I598	—	0.978	Q5I598 →
Q641Y5	—	0.978	Q641Y5 →
Q6ESI7	—	0.978	Q6ESI7 →
Q5R981	—	0.977	Q5R981 →
PRMT5	Protein arginine N-methyltransferase 5	0.977	landscape →
O42131	—	0.977	O42131 →
A2VE39	—	0.977	A2VE39 →
F4JVN6	—	0.977	F4JVN6 →
Q0MQB7	—	0.977	Q0MQB7 →
Q5R698	—	0.977	Q5R698 →
P0CB89	—	0.977	P0CB89 →
Q9ER88	—	0.976	Q9ER88 →
Q9FNA3	—	0.976	Q9FNA3 →
Q0MQB6	—	0.976	Q0MQB6 →